GlassScriptPhysician profile
Telisha Bernal
NPI 1871152496
$9,308.12
in general payments reported to CMS, 2019-2025
36 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,547 · 2022: $3,410 · 2023: $833 · 2024: $1,177 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.58 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,615.38 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,058.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $527.30 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.33 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $462.92 | 2021-2022 | |
| Nevro Corp. | $458.06 | 2021-2024 | Senza |
| Esperion Therapeutics, INC. | $397.44 | 2021 | |
| Corcept Therapeutics | $343.59 | 2022-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $334.67 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $257.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.56 | 2021-2023 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $232.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $203.09 | 2021-2023 | Seglentis, Livalo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.39 | 2021-2022 | |
| Astellas Pharma US INC | $178.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Madrigal Pharmaceuticals | $113.00 | 2024 | Rezdiffra |
| Angiodynamics, INC. | $86.29 | 2024 | Auryon Laser System 100-120 Vac |
| Dexcom, INC. | $76.08 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.81 | 2021 | |
| Intercept Pharmaceuticals, INC. | $64.42 | 2022 | |
| Antares Pharma, INC. | $54.99 | 2022 | |
| Pfizer INC. | $53.88 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $42.17 | 2021 | |
| Insulet Corporation | $34.29 | 2022 | |
| Organon LLC | $31.10 | 2023 | Nexplanon |
| Neurocrine Biosciences, INC. | $25.48 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $16.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.66 | 2022 | |
| Corium, LLC | $16.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2022 | |
| Shield Therapeutics INC | $13.44 | 2023 | Accrufer |
| Arbor Pharmaceuticals, INC. | $12.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Telisha Bernal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.